Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Viatris Inc (VTRS) vs Vanguard High Dividend Yield ETF (VYM) Price & Performance

Viatris IncTrade
Vanguard High Dividend Yield ETFTrade

Price performance (Past 24H)

Key statistics

Viatris Inc vs Vanguard High Dividend Yield ETF — how do they compare? Viatris Inc trades at $16.45 (market cap $19.09B), while Vanguard High Dividend Yield ETF trades at $163. The key difference: Viatris Inc pays a 2.89% dividend while Vanguard High Dividend Yield ETF pays none. Which is the better fit depends on your goals.

VTRSVYM
Market Cap
$19.09B
Sector
Health
52-Week High
$17.86$167.03
52-Week Low
$9.49$137.47
Enterprise Value
$31.21B
Dividend Yield
2.89%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Viatris Inc

Viatris (VTRS) trades at $16.61, down 1.6% over the past 24 hours. The stock exhibits a mixed technical picture with a bullish overall signal but bearish moving averages. Fundamentally, the company reported a net loss of $3.51 billion in 2025 despite revenue of $14.30 billion, though recent quarters have shown earnings beats. Positive cash flow generation and a dividend payment highlight financial stability, while analyst sentiment is mixed with a majority hold rating.

The outlook for VTRS hinges on its ability to return to profitability and sustain operational improvements. Investment opportunities include strong cash flow, deleveraging progress, and pipeline developments, but risks involve persistent net losses, competitive pressures, and potential regulatory impacts from proposed generic drug tariffs.

Vanguard High Dividend Yield ETF

VYM trades at $163.52, down 0.43% with a bearish technical signal from moving averages while oscillators remain neutral. The ETF's forward P/E ratio of 18.85x provides a valuation advantage over SPY, with financial sector exposure potentially benefiting from rising Treasury yields. Recent analysis highlights strong 16% YTD total return and lower volatility compared to the broader market.

The outlook remains cautiously optimistic given VYM's valuation discount and dividend stability, though technical weakness and yield compression to 2.20-2.22% present near-term headwinds. Key risks include sector concentration in financials and market sensitivity to interest rate changes, while institutional sentiment appears balanced between yield appeal and growth concerns.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Viatris Inc

Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).

Read more on VTRS

About Vanguard High Dividend Yield ETF

The advisor employs an indexing investment approach designed to track the performance of the index, which consists of common stocks of companies that pay dividends that generally are higher than average. The advisor attempts to replicate the target index by investing all, or substantially all, of the fund's assets in the stocks that make up the index, holding each stock in approximately the same proportion as its weighting in the index.

Read more on VYM